Natco-Lupin get USFDA’s nod for Eribulin Mesylate injection

Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection

Lupin and Natco obtain FDA approval for Eribulin Mesylate generic, bioequivalent to Eisai's Halaven (estimated $43.7M U.S. annual sales). Generic market entry pressures oncology drug pricing and accelerates payer shift toward cost-effective alternatives.